Acadian Asset Management LLC acquired a new stake in shares of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP – Free Report) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 31,736 shares of the biotechnology company’s stock, valued at approximately $113,000.
Several other large investors also recently modified their holdings of the stock. Two Sigma Investments LP bought a new position in shares of Oramed Pharmaceuticals during the first quarter valued at $1,104,000. Renaissance Technologies LLC acquired a new stake in Oramed Pharmaceuticals in the 2nd quarter valued at about $1,647,000. JPMorgan Chase & Co. increased its holdings in shares of Oramed Pharmaceuticals by 1,796.3% in the second quarter. JPMorgan Chase & Co. now owns 336,549 shares of the biotechnology company’s stock valued at $1,541,000 after purchasing an additional 318,801 shares in the last quarter. BlackRock Inc. raised its position in shares of Oramed Pharmaceuticals by 17.4% during the first quarter. BlackRock Inc. now owns 1,830,166 shares of the biotechnology company’s stock worth $15,832,000 after acquiring an additional 271,559 shares during the last quarter. Finally, Millennium Management LLC boosted its holdings in Oramed Pharmaceuticals by 59.6% in the second quarter. Millennium Management LLC now owns 580,383 shares of the biotechnology company’s stock valued at $2,658,000 after acquiring an additional 216,823 shares during the last quarter. 5.82% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
Separately, StockNews.com assumed coverage on Oramed Pharmaceuticals in a report on Thursday, October 5th. They set a “hold” rating for the company.
Oramed Pharmaceuticals Stock Performance
ORMP opened at $2.16 on Tuesday. The company has a fifty day moving average price of $2.27 and a two-hundred day moving average price of $3.05. The firm has a market capitalization of $87.13 million, a PE ratio of -5.27 and a beta of 1.84. Oramed Pharmaceuticals Inc. has a 52 week low of $1.67 and a 52 week high of $13.73.
Oramed Pharmaceuticals Profile
Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. The company's product portfolio includes ORMD-0801 Type 2, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes; ORMD-0801, Phase 2 oral insulin capsule for non-alcoholic steatohepatitis, a progressive liver diseases; and ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes.
- Five stocks we like better than Oramed Pharmaceuticals
- What Are the U.K. Market Holidays? How to Invest and Trade
- The most upgraded stocks in November have two things in common
- How to Invest in Cannabis, Step by Step
- Monday.com rocked earnings like it’s the weekend
- What are stock market earnings reports?
- Plan to own one retailer? Make it this one
Receive News & Ratings for Oramed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.